Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of the American College of Cardiology|November 3, 2022
Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac DiseaseMichael A Portman, Jeffrey P Jacobs, Jane W Newburger, et al.Research and Practice in Thrombosis and Haemostasis|July 21, 2020
The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic diseaseCornelia Heleen van Ommen, Manuela Albisetti, Anthony K Chan, et al.Cardiology in the Young|August 4, 2021
ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolismMihir D Bhatt, Michael A Portman, Felix Berger, et al.Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|March 27, 2015
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular interventionMarco J D Tangelder, Chuke E Nwachuku, Michael Jaff, et al.Journal of the American Heart Association|May 15, 2025
Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF TrialGeorge D Dangas, Martin Unverdorben, Johny Nicolas, et al.The Lancet. Global Health|April 12, 2017
Complementary feeding at 4 versus 6 months of age for preterm infants born at less than 34 weeks of gestation: a randomised, open-label, multicentre trialShuchita Gupta, Ramesh Agarwal, Kailash Chandra Aggarwal, et al.Journal of the American Heart Association|October 30, 2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialChristina L Fanola, Christian T Ruff, Sabina A Murphy, et al.Stroke|June 21, 2014
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48Robert P Giugliano, Christian T Ruff, Natalia S Rost, et al.JACC. Advances|June 28, 2024
Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVRRoxana Mehran, Alessandro Spirito, James Jin, et al.Journal of Thrombosis and Haemostasis : JTH|August 29, 2021
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxabanFloris T M Bosch, Frits I Mulder, Menno V Huisman, et al.Pageof 3